Q-omics provides the consensus-scored NUDT19P5 profile across patient tissues and cancer cell-line models. NUDT19P5 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NUDT19P5 is differentially expressed in 6, with the highest sampling consensus in STAD. Additionally, NUDT19P5 RNA expression shows 15,362 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight MESO, STAD, and BRCA as cancer lineages where NUDT19P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUDT19P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUDT19P5 survival associations across molecular data types. NUDT19P5 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUDT19P5 RNA expression–survival associations across cancer types. High NUDT19P5 expression shows unfavorable associations in MESO, LGG, KIRC, THYM, UVM and KICH. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NUDT19P5 RNA expression.
This table summarizes NUDT19P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NUDT19P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUDT19P5 shows lower tumor expression in THCA and higher tumor expression in STAD, KIRC, PRAD, KICH and LUSC. The STAD box plot shows higher NUDT19P5 RNA expression in tumor versus normal tissue (log2 FC = +0.444, t-test p = .001).
This table shows molecular features associated with NUDT19P5 in patient tissues and cancer cell lines. In patient samples, NUDT19P5 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
